17:00 EST 6 Feb 2019 | Businesswire

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology
company, announced today that the company has granted Japanese animal
health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an
exclusive license to develop and
commercialize its investigational DNA vaccine, ITI-002, for canine atopic
dermatitis and other companion animal allergies. The therapy was developed
using ITI’s proprietary UNITE™ (UNiversal Intracellular Targeted Expression)
platform, which harnesses the natural biochemistry of humans and other mammals
to develop vaccines that trigger broad immune responses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190206005659/en/

“Our UNITE platform continues to generate
sophisticated investigational DNA and RNA vaccines for indications in both
humans and animals,” said Dr. William Hearl, CEO of Immunomic
Therapeutics. “Investigating the application of our
technology to this significant health problem for dogs has been an important
part of our allergy research and development program for the last few years. We
are very pleased to have such a strong animal health partner in ZENOAQ to
continue the development process and strive to bring this product to market. We
are confident with their extensive experience in the animal health market and
believe that they will be able to commercialize this potentially high-value
treatment for dog allergy worldwide.”

Atopic dermatitis is a chronic inflammatory skin condition that affects an
estimated 10-15 percent of dogs1. The disease is caused by an
allergic reaction to common environmental substances, such as grass, dust
mites, and mold. ITI’s experimental vaccine is designed to build tolerance to a
number of these allergens through the delivery of key nucleotide sequences (for
example, those encoding for dust mites).

“Canine atopic dermatitis is a life-long condition
that negatively impacts both the animal and its owner,” said ZENOAQ
President Toshikazu Fukui. “Immunomic’s immunotherapy platform combines many
technological and scientific advances, producing vaccines that could really
usher in a new era of treatment, targeting the root cause of the inflammation.”

As part of the agreement, ZENOAQ will also receive exclusive rights to
option other UNITE-based therapies and indications within animal health,
including oncology.

About UNITE

ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted
Expression, is thought to work by encoding the Lysosomal Associated Membrane
Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or
RNA) have the potential to utilize the body’s natural biochemistry to develop a
broad immune response including antibody production, cytokine release and
critical immunological memory. This approach could put UNITE technology at the
crossroads of immunotherapies in a number of illnesses, including cancer,
allergy and infectious diseases. UNITE is currently being employed in Phase II
clinical trials as a cancer immunotherapy. ITI is also collaborating with
academic centers and biotechnology companies to study the use of UNITE in
cancer types of high mortality, including cases where there are limited
treatment options like glioblastoma and acute myeloid leukemia. ITI believes
that these early clinical studies may provide a proof of concept for UNITE
therapy in cancer, and if successful, set the stage for future studies,
including combinations in these tumor types and others. Preclinical data is
currently being developed to explore whether LAMP nucleic acid constructs may
amplify and activate the immune response in highly immunogenic tumor types and
be used to create immune responses to tumor types that otherwise do not provoke
an immune response and be used to create immune responses to tumor types that otherwise
do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage
biotechnology company pioneering the study of the LAMP-based nucleic acid
immunotherapy platforms. These investigational technologies have the potential
to alter how we use immunotherapy for cancer, allergies and animal health. ITI
has entered into a significant licensing agreement with Astellas Pharma Inc. to
explore the use of LAMP-Vax, the precursor to UNITE, an immunotherapy platform,
for use in the prevention and treatment of allergic diseases. For information
about ITI and UNITE technology, visit www.immunomix.com.

About Zenoaq (http://www.zenoaq.jp/english/)

Established in 1946, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd.) is a leading
animal health company in Japan. With a workforce of nearly 700 employees and
the generation of about ¥32.7 billion in sales (approximately US$297.3 million)
in the 2016 fiscal year, ZENOAQ has a solid business model focused on R&D,
manufacturing and importation of animal health products, contributing to a
broad product portfolio for production and companion animals. In addition,
ZENOAQ, headquartered in Fukushima, has the widest distribution network for
veterinary products in Japan, supported by a strong direct sales force. In June
2014, ZENOAQ launched Allermmune HDM, a first-of-its-kind desensitization
therapy for house dust mite-induced canine atopic dermatitis, reflecting the
company’s increased focus on an innovative pipeline for the companion animal
market. ZENOAQ’s partners include Boehringer Ingelheim Animal Health, CEVA SA,
Vetoquinol, Mars, Intervet, DSM Nutrition as well as IDEXX Laboratories.

1 Hillier A, Griffin CE. The ACVD task force on canine atopic
dermatitis (I): incidence and prevalence. Vet Immunol
Immunopathology. 2001;81(3–4):147–151. doi: 10.1016/S0165-2427(01)00296-3.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190206005659/en/

Immunomic Therapeutics, Inc.
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

ZENOAQ
Akemi Sakai
ZENOAQ Tokyo Branch Office
sakai-akemi@zenoaq.jp
+81 3 5282-2485

The post Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ appeared first on Life Sciences Greenhouse of Central Pennsylvania.